| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquiring evidence for precision prostate cancer care
|
Mateo, J.
|
|
|
28 |
5 |
p. 916-917
|
article
|
| 2 |
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
|
Bleiberg, H.
|
|
|
28 |
5 |
p. 922-930
|
article
|
| 3 |
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
|
Sartor, O.
|
|
|
28 |
5 |
p. 1090-1097
|
article
|
| 4 |
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
|
Monk, B.J.
|
|
|
28 |
5 |
p. 996-1004
|
article
|
| 5 |
A step towards the harmonization of clinical trials inform consent forms
|
Remon, J.
|
|
|
28 |
5 |
p. 910-912
|
article
|
| 6 |
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
|
Petrella, T.
|
|
|
28 |
5 |
p. 1042-1049
|
article
|
| 7 |
CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification
|
Pilati, C.
|
|
|
28 |
5 |
p. 1032-1035
|
article
|
| 8 |
Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?
|
Tam, C.S.
|
|
|
28 |
5 |
p. 920-921
|
article
|
| 9 |
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
|
Lee, J.H.
|
|
|
28 |
5 |
p. 1130-1136
|
article
|
| 10 |
Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015
|
Vivot, A.
|
|
|
28 |
5 |
p. 1111-1116
|
article
|
| 11 |
Data resources for the identification and interpretation of actionable mutations by clinicians
|
Prawira, A.
|
|
|
28 |
5 |
p. 946-957
|
article
|
| 12 |
Editorial Board
|
|
|
|
28 |
5 |
p. ii-iii
|
article
|
| 13 |
Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations
|
Böger, C.
|
|
|
28 |
5 |
p. 1005-1014
|
article
|
| 14 |
European cancer mortality predictions for the year 2017, with focus on lung cancer
|
Malvezzi, M.
|
|
|
28 |
5 |
p. 1117-1123
|
article
|
| 15 |
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
|
Suenaga, M.
|
|
|
28 |
5 |
p. 1015-1022
|
article
|
| 16 |
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial
|
Lesurf, R.
|
|
|
28 |
5 |
p. 1070-1077
|
article
|
| 17 |
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial
|
Guberina, M.
|
|
|
28 |
5 |
p. 1084-1089
|
article
|
| 18 |
High-risk human papillomavirus in anal squamous cell carcinoma: a ‘conservative’ leading role
|
Ravenda, P.S.
|
|
|
28 |
5 |
p. 1160
|
article
|
| 19 |
HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma
|
Chen, X.
|
|
|
28 |
5 |
p. 1105-1110
|
article
|
| 20 |
Immunotherapy and epithelial ovarian cancer: a double-edged sword?
|
Ray-Coquard, I.
|
|
|
28 |
5 |
p. 909-910
|
article
|
| 21 |
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study
|
Dréno, B.
|
|
|
28 |
5 |
p. 1137-1144
|
article
|
| 22 |
Intratumoral heterogeneity in gastric cancer: a new challenge to face
|
Alsina, M.
|
|
|
28 |
5 |
p. 912-913
|
article
|
| 23 |
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma
|
Teckie, S.
|
|
|
28 |
5 |
p. 1064-1069
|
article
|
| 24 |
Looking beyond drivers and passengers in cancer genome sequencing data
|
De, S.
|
|
|
28 |
5 |
p. 938-945
|
article
|
| 25 |
MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk
|
Zhang, L.
|
|
|
28 |
5 |
p. 1124-1129
|
article
|
| 26 |
Modeling individual and relative accuracy of screening tools in geriatric oncology
|
Bellera, C.A.
|
|
|
28 |
5 |
p. 1152-1157
|
article
|
| 27 |
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
|
Mato, A.R.
|
|
|
28 |
5 |
p. 1050-1056
|
article
|
| 28 |
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
|
Besse, B.
|
|
|
28 |
5 |
p. 1078-1083
|
article
|
| 29 |
Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis
|
Maisonneuve, P.
|
|
|
28 |
5 |
p. 985-995
|
article
|
| 30 |
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
|
Gopal, A.K.
|
|
|
28 |
5 |
p. 1057-1063
|
article
|
| 31 |
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?
|
Vlachostergios, P.J.
|
|
|
28 |
5 |
p. 914-916
|
article
|
| 32 |
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
|
Dienstmann, R.
|
|
|
28 |
5 |
p. 1023-1031
|
article
|
| 33 |
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
|
Mahal, B.A.
|
|
|
28 |
5 |
p. 1098-1104
|
article
|
| 34 |
Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma
|
Balagué, O.
|
|
|
28 |
5 |
p. 918-920
|
article
|
| 35 |
Reply to ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by J. Furlanetto et al.
|
Daly, L.E.
|
|
|
28 |
5 |
p. 1161-1162
|
article
|
| 36 |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
|
Ott, P.A.
|
|
|
28 |
5 |
p. 1036-1041
|
article
|
| 37 |
Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient
|
Romero-Laorden, N.
|
|
|
28 |
5 |
p. 1158-1159
|
article
|
| 38 |
Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews
|
Herrmann, D.
|
|
|
28 |
5 |
p. 931-937
|
article
|
| 39 |
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
|
Auclin, E.
|
|
|
28 |
5 |
p. 958-968
|
article
|
| 40 |
Subjective and objective taste and smell changes in cancer
|
Spotten, L.E.
|
|
|
28 |
5 |
p. 969-984
|
article
|
| 41 |
Table of Contents
|
|
|
|
28 |
5 |
p. iv-vi
|
article
|
| 42 |
The role of AR polyQ tract in male breast carcinoma: lesson from an SBMA case
|
Querin, G.
|
|
|
28 |
5 |
p. 1160-1161
|
article
|
| 43 |
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape
|
Vis, D.J.
|
|
|
28 |
5 |
p. 1145-1151
|
article
|
Journal description